ArticleTranslational oncology2025
Integrated transcriptome and single-cell RNA sequencing analysis revealed the prognostic significance of GBP4 in pancreatic adenocarcinoma.
Article in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Article
- Reading the tumour at single-cell resolution: Original research in the Precision Therapeutics special issue.Translational oncology · 2026Article
- Molecular landscape and clinical translation of DNA damage response alterations in solid tumors: A pan-cancer perspective on precision oncology.Neoplasia (New York, N.Y.) · 2026Review
- The interplay between tumor-intrinsic KRT6A and host-derived immune-nutritional status (PNI) defines prognosis in resectable PDAC.Scientific reports · 2026Article
- Comprehensive analysis of circRNA-miRNA-mRNA networks to reveal potential cell death, inflammation and oxidative stress-related targets for postoperative cognitive dysfunction.Frontiers in aging neuroscience · 2026Article
- Discovery and validation of programmed cell death-associated key biomarker genes in ischemic stroke via ssGSEA/WGCNA and LASSO-SVM-RFE.Frontiers in molecular biosciences · 2026Article
- ULBP1 is a prognostic biomarker associated with immune suppression in breast cancer.Frontiers in oncology · 2026Article
- Identification and Validation of a Two-Gene NK Cell-Related Risk Model for COPD: Integration of Single-Cell and Bulk RNA-Seq Analysis.International journal of chronic obstructive pulmonary disease · 2026Article
- Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of GBP4 in cancer has been preliminarily identified, yet its specific function in patients with pancreatic adenocarcinoma (PAAD) remains unclear. The aim of this study is to determine the impact of the GBP4 gene on PAAD.
methodsTranscriptomics and single-cell RNA sequencing (scRNA-seq) data were obtained from public databases. Prognostic genes were screened using univariate Cox and least absolute shrinkage and selection operator (LASSO) regression to construct and validate the model. Pathway enrichment and immune microenvironment analyses explored PAAD mechanisms, while scRNA-seq revealed key cell populations and dynamic gene expression. Functional experiments of GBP4 on tumor cell growth were investigated in vitro and in vivo.
resultsThis study identified 5 prognostic genes related to the GBP4 gene in PAAD, including GBP2, KRT6A, MMP7, BCAT1, and SPRR1A. The risk model showed validity and generalizability, with "cell cycle" pathway enrichment in high-risk groups and metabolic pathways in low-risk groups. Immune cell infiltration (e.g., central memory CD8 T cells, activated B cells) differed significantly between risk groups (p < 0.01) and correlated with prognostic genes. Ductal cells were key cells, with prognostic gene expression varying during differentiation. In vitro functional assays confirmed the role of GBP4 in promoting pancreatic cancer cell proliferation, migration, and invasion. Moreover, silencing of GBP4 inhibited tumor growth in vivo, whereas GBP4 overexpression increased the tumor growth.
conclusionThis study identifies GBP4-related prognostic genes and demonstrates the role of GBP4 in pancreatic cancer progression, providing new perspectives for prognostic prediction and therapeutic targeting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.